NEO vs TGTX: fair value comparison
NeoGenomics, Inc. and TG Therapeutics, Inc. · Updated 2026-10-19
NEO's estimate rests on a sector-average multiple, which TickrTrends does not publish as a verdict. TGTX is still awaiting a full valuation verdict under our six-validated-windows standard. Within Healthcare, NEO currently ranks higher by quality score.
| NEO | TGTX | |
|---|---|---|
| Verdict | Awaiting full valuation | Awaiting full valuation |
| Last price | $16.65 | $53.97 |
| 12-month range | $7.19–$19.91 | $26.94–$59.06 |
| Rank by discount to fair value | — | — |
| Rank by quality score | #128 of 301 Healthcare | #129 of 301 Healthcare |
| Quality grade | D | D |
| Leverage | Moderate | Moderate |
| Margin trend | Contracting | Contracting |
| Revenue growth | Strong | Strong |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Mixed | Mixed |
| 52-week position | The upper-middle quarter | The top quarter |
Full single-stock breakdowns: NEO fair value analysis · TGTX fair value analysis